Searchable abstracts of presentations at key conferences in endocrinology

ea0065op4.3 | Bone and Calcium | SFEBES2019

Mendelian randomization and machine learning to assess the causal association of Type 2 Diabetes with osteoporosis and fragility fractures

Deshmukh Harshal , Papageorgiou Maria , Sathyapalan Thozhukat

Background: We used Mendelian randomization and machine learning (gradient boosting) to assess the causal association of Type 2 Diabetes with osteoporosis.Methods: We selected 155 SNPs associated with type 2 diabetes and glycaemic and insulin-related traits reported in previous studies (1,2) and studied the association with Heel bone mineral density (BMD)) (n= 4 72 996) and risk of fragility fractures (26 157 cases and 17 807 controls) in UKBiob...

ea0077p107 | Reproductive Endocrinology | SFEBES2021

A randomised controlled trial on the effect of very-low-calorie diet (VLCD) vs. an energy deficit diet, in women with the polycystic ovary syndrome (PCOS) – remission PCOS

Deshmukh Harshal , Papageorgiou Maria , Wells Liz , Akbar Shahzad , Strudwick Tom , Reid Marie , Sathyapalan Thozhukat

PCOS is the most common endocrine disorder affecting the women of reproductive age group and weight loss is the mainstay of management of PCOS. We performed an open-label randomised controlled trial to compare the effects of a conventional energy deficit approach (-600 kcal/day of the total energy requirements) vs. a very low-calorie diet (VLCD: 800 kcal/day) on free androgen index (FAI), body weight, and metabolic markers in women with PCOS. Forty-one eligible patients were r...

ea0059p156 | Obesity & metabolism | SFEBES2018

Randomised trial of empagliflozin versus metformin in polycystic ovary syndrome

Javed Zeeshan , Papageorgiou Maria , Kilpatrick Eric , Abbas Jehangir , Khan Amer , Rigby Alan , Atkin Stephen , Sathyapalan Thozhukat

Background: Empagliflozin is a sodium-glucose-cotransporter-2 that improves cardiovascular risk and weight loss in patients with type 2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit in PCOS.Methods: A randomised, open-label study in 40 overweight and obese women with PCOS treated with either empagliflozin 25 mg or metformin 1500mg daily for 12 weeks....